...
search icon
stro-img

Sutro Biopharma, Common Stock

STRO

NMQ

$2.035

+$0.07

(3.55%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$156.67M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
650.59K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.17
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$1.67 L
$6.13 H
$2.035

About Sutro Biopharma, Common Stock

Sutro Biopharma, Inc. operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer. The company's pre-clinical product candidates include STRO-003, an ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors and hematological cancers; and STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including cervical, lung, and breast cancer. Sutro Biopharma, Inc. has collaboration and license agreements with Merck Sharp & Dohme Corporation to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; Vaxcyte to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases; Tasly Biopharmaceuticals Co., Ltd. to develop and commercialize STRO-002 in Greater China; EMD Serono to develop ADCs for multiple cancer targets; and Astellas Pharma Inc. to develop immunostimulatory ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameSTROSectorS&P500
1-Week Return7.65%1.15%2.3%
1-Month Return5.35%2.47%1.9%
3-Month Return-44.19%-5.91%4%
6-Month Return-50.63%-4.4%9.38%
1-Year Return-55.83%1.51%25.5%
3-Year Return-81.08%10.18%37.9%
5-Year Return-83.56%35.76%83.12%
10-Year Return-87.04%99.27%194.91%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue42.74M42.72M61.88M67.77M153.73M[{"date":"2019-12-31","value":27.8,"profit":true},{"date":"2020-12-31","value":27.79,"profit":true},{"date":"2021-12-31","value":40.25,"profit":true},{"date":"2022-12-31","value":44.08,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Cost of Revenue65.61M76.96M9.77M8.29M6.82M[{"date":"2019-12-31","value":85.25,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":12.7,"profit":true},{"date":"2022-12-31","value":10.77,"profit":true},{"date":"2023-12-31","value":8.86,"profit":true}]
Gross Profit(22.88M)(34.24M)52.11M59.48M146.91M[{"date":"2019-12-31","value":-15.57,"profit":false},{"date":"2020-12-31","value":-23.31,"profit":false},{"date":"2021-12-31","value":35.47,"profit":true},{"date":"2022-12-31","value":40.49,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Margin(53.53%)(80.14%)84.21%87.77%95.57%[{"date":"2019-12-31","value":-56.01,"profit":false},{"date":"2020-12-31","value":-83.86,"profit":false},{"date":"2021-12-31","value":88.11,"profit":true},{"date":"2022-12-31","value":91.84,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Expenses98.20M113.78M160.40M196.72M243.01M[{"date":"2019-12-31","value":40.41,"profit":true},{"date":"2020-12-31","value":46.82,"profit":true},{"date":"2021-12-31","value":66.01,"profit":true},{"date":"2022-12-31","value":80.95,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Income(55.47M)(71.06M)(98.52M)(128.94M)(89.28M)[{"date":"2019-12-31","value":-5546800000,"profit":false},{"date":"2020-12-31","value":-7105700000,"profit":false},{"date":"2021-12-31","value":-9852400000,"profit":false},{"date":"2022-12-31","value":-12894300000,"profit":false},{"date":"2023-12-31","value":-8927800000,"profit":false}]
Total Non-Operating Income/Expense3.80M36.36M(9.57M)12.35M(1.57M)[{"date":"2019-12-31","value":10.45,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-26.33,"profit":false},{"date":"2022-12-31","value":33.96,"profit":true},{"date":"2023-12-31","value":-4.31,"profit":false}]
Pre-Tax Income(55.74M)(32.13M)(105.54M)(116.70M)(88.60M)[{"date":"2019-12-31","value":-5574400000,"profit":false},{"date":"2020-12-31","value":-3212800000,"profit":false},{"date":"2021-12-31","value":-10553800000,"profit":false},{"date":"2022-12-31","value":-11670400000,"profit":false},{"date":"2023-12-31","value":-8860100000,"profit":false}]
Income Taxes276.00K4.08M3.14M2.50M18.19M[{"date":"2019-12-31","value":1.52,"profit":true},{"date":"2020-12-31","value":22.41,"profit":true},{"date":"2021-12-31","value":17.24,"profit":true},{"date":"2022-12-31","value":13.74,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Income After Taxes(56.02M)(36.20M)(108.67M)(119.20M)(106.79M)[{"date":"2019-12-31","value":-5602000000,"profit":false},{"date":"2020-12-31","value":-3620500000,"profit":false},{"date":"2021-12-31","value":-10867500000,"profit":false},{"date":"2022-12-31","value":-11920400000,"profit":false},{"date":"2023-12-31","value":-10679300000,"profit":false}]
Income From Continuous Operations(55.74M)(32.13M)(105.54M)(119.20M)(172.45M)[{"date":"2019-12-31","value":-5574400000,"profit":false},{"date":"2020-12-31","value":-3212800000,"profit":false},{"date":"2021-12-31","value":-10553800000,"profit":false},{"date":"2022-12-31","value":-11920400000,"profit":false},{"date":"2023-12-31","value":-17245200000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(55.74M)(36.20M)(108.67M)(119.20M)(106.79M)[{"date":"2019-12-31","value":-5574400000,"profit":false},{"date":"2020-12-31","value":-3620500000,"profit":false},{"date":"2021-12-31","value":-10867500000,"profit":false},{"date":"2022-12-31","value":-11920400000,"profit":false},{"date":"2023-12-31","value":-10679300000,"profit":false}]
EPS (Diluted)(2.42)(2.46)(2.29)(2.44)(1.78)[{"date":"2019-12-31","value":-242,"profit":false},{"date":"2020-12-31","value":-246,"profit":false},{"date":"2021-12-31","value":-229,"profit":false},{"date":"2022-12-31","value":-244,"profit":false},{"date":"2023-12-31","value":-178,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

STRO
Cash Ratio 2.96
Current Ratio 3.09

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

STRO
ROA (LTM) -18.40%
ROE (LTM) -110.89%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

STRO
Debt Ratio Lower is generally better. Negative is bad. 0.75
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.25

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

STRO
Trailing PE NM
Forward PE NM
P/S (TTM) 1.01
P/B 1.46
Price/FCF NM
EV/R 0.36
EV/Ebitda 0.41

FAQs

What is Sutro Biopharma share price today?

Sutro Biopharma (STRO) share price today is $2.035

Can Indians buy Sutro Biopharma shares?

Yes, Indians can buy shares of Sutro Biopharma (STRO) on Vested. To buy Sutro Biopharma from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in STRO stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Sutro Biopharma be purchased?

Yes, you can purchase fractional shares of Sutro Biopharma (STRO) via the Vested app. You can start investing in Sutro Biopharma (STRO) with a minimum investment of $1.

How to invest in Sutro Biopharma shares from India?

You can invest in shares of Sutro Biopharma (STRO) via Vested in three simple steps:

  • Click on Sign Up or Invest in STRO stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Sutro Biopharma shares
What is Sutro Biopharma 52-week high and low stock price?

The 52-week high price of Sutro Biopharma (STRO) is $6.13. The 52-week low price of Sutro Biopharma (STRO) is $1.67.

What is Sutro Biopharma price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Sutro Biopharma (STRO) is

What is Sutro Biopharma price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Sutro Biopharma (STRO) is 1.46

What is Sutro Biopharma dividend yield?

The dividend yield of Sutro Biopharma (STRO) is 0.00%

What is the Market Cap of Sutro Biopharma?

The market capitalization of Sutro Biopharma (STRO) is $156.67M

What is Sutro Biopharma’s stock symbol?

The stock symbol (or ticker) of Sutro Biopharma is STRO

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top